American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
JI
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
$15.64
-1.51%
OTC: JHPCY · 15-min delayed
JHPCYOTC
About Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
JIANGSU HENGRUI PHARM CO
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
OTC: JHPCY
$15.64
-1.51%
15-minute delayed · data by Polygon.io
Past year
$15.64
$18.00
52-week range
- Dividend yield
- 0.37%
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Trading 13% below its 52-week high.
- Pays a dividend yielding about 0.37% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR.
Write a review
Newsroom
News about Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Precision-Drug maker Impact Therapeutics Ignites IPO Frenzy
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
Kailera Therapeutics Announces Pricing of Initial Public Offering
Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
Endometriosis Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
News & sentiment via Polygon.io
Explore
Browse all →
